Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Moderna Inc. Revenue & Financial Statements
Moderna Inc. reported revenue of $1.9B for the fiscal year ended December 31, 2025, down 39.9% year over year, with net income of $(2.8B) and diluted EPS of $-7.26.
- Company
- Moderna Inc. MRNA · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 18.5B | 19.3B | 6.8B | 3.2B | 1.9B |
| Cost of revenue | 2.6B | 5.4B | 4.7B | 1.5B | 868.0M |
| Gross profit | 15.9B | 13.8B | 2.2B | 1.8B | 1.1B |
| Operating income | 13.3B | 9.4B | (4.2B) | (3.9B) | (3.1B) |
| Pretax income | 13.1B | 9.4B | (4.1B) | (3.7B) | (113.0M) |
| Net income | 12.2B | 8.4B | (4.7B) | (3.6B) | (2.8B) |
| Diluted EPS | 28.29 | 20.12 | -12.33 | -9.28 | -7.26 |
| EBITDA | 13.5B | 9.8B | (3.6B) | (3.8B) | (2.9B) |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 167.0M | 241.0M | 1.9B | 966.0M | 108.0M | 142.0M | 1.0B | 678.0M |
| Cost of revenue | 96.0M | 115.0M | 514.0M | 739.0M | 90.0M | 119.0M | 207.0M | 452.0M |
| Gross profit | 71.0M | 126.0M | 1.3B | 227.0M | 18.0M | 23.0M | 809.0M | 226.0M |
| Operating income | (1.3B) | (1.4B) | (70.0M) | (1.2B) | (1.1B) | (907.0M) | (260.0M) | (857.0M) |
| Pretax income | (1.2B) | (1.3B) | 21.0M | (1.2B) | (964.0M) | (818.0M) | (187.0M) | (799.0M) |
| Net income | (1.2B) | (1.3B) | 13.0M | (1.1B) | (971.0M) | (825.0M) | (200.0M) | (826.0M) |
| Diluted EPS | -3.07 | -3.33 | 0.03 | -2.91 | -2.52 | -2.13 | -0.51 | -2.11 |
| EBITDA | (1.2B) | (1.3B) | (19.0M) | (1.2B) | (1.0B) | (851.0M) | (209.0M) | (791.0M) |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 24.7B | 25.9B | 18.4B | 14.1B | 12.3B |
| Current assets | 16.1B | 13.4B | 10.3B | 8.1B | 6.5B |
| Cash & equivalents | 6.8B | 3.2B | 2.9B | 1.9B | 2.6B |
| Total liabilities | 10.5B | 6.7B | 4.6B | 3.2B | 3.7B |
| Current liabilities | 9.1B | 4.9B | 3.0B | 2.2B | 2.0B |
| Long-term debt | — | — | — | — | 590.0M |
| Total debt | — | — | — | — | 590.0M |
| Stockholders’ equity | 14.1B | 19.1B | 13.9B | 10.9B | 8.7B |
| Net debt | — | — | — | — | (2.0B) |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 13.6B | 5.0B | (3.1B) | (3.0B) | (1.9B) |
| Investing cash flow | (8.5B) | (5.2B) | 4.2B | 1.9B | 1.9B |
| Financing cash flow | (873.0M) | (3.4B) | (1.4B) | 56.0M | 593.0M |
| Capital expenditure | 284.0M | 400.0M | 707.0M | 1.1B | 192.0M |
| Free cash flow | 13.3B | 4.6B | (3.8B) | (4.1B) | (2.1B) |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 142.0M | 226.0M | 305.0M | 429.0M | 483.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every MRNA filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.